CSF-1R Antibody and JAK Inhibitor Combination for cGVHD

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Chronic graft-versus-host disease (cGVHD) is a severe complication of allogeneic hematopoietic cell transplantation that affects various organs, leading to a reduced quality of life and increased non-relapse mortality, with current treatments like systemic corticosteroids being ineffective and associated with significant side effects.

Innovation Solution

Administering a therapeutically effective amount of a JAK inhibitor, such as ruxolitinib, in combination with an antibody that binds to colony stimulating factor 1 receptor (CSF-1R), specifically designed with defined VH and VL CDR sequences, to treat cGVHD.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If systemic corticosteroids are used to treat cGVHD, then treatment effectiveness is improved, but side effects and toxicity increase

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects and toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic parameters by switching from corticosteroids to a combination of a CSF-1R antibody (axatilimab) and a JAK inhibitor (ruxolitinib). This parameter change achieves treatment effectiveness while avoiding the harmful side effects associated with prolonged corticosteroid use, such as infections, myopathy, cataract, diabetes, hypertension, bone mass decline, and avascular necrosis.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite therapeutic approach by combining two mechanisms of action: a monoclonal antibody (axatilimab) that binds to CSF-1R and a JAK inhibitor (ruxolitinib) that inhibits JAK1/2 signaling. This composite therapy achieves synergistic effects in treating cGVHD while reducing the toxicity profile compared to corticosteroid monotherapy.

Inventive Principle:

Principle #40Composite materials

2Reliability

If prolonged systemic corticosteroid treatment is used, then cGVHD control is improved, but quality of life deteriorates

Engineering Contradiction:

ImprovecGVHD controlVSAvoidquality of life

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the treatment parameters from prolonged corticosteroid therapy to a finite-duration combination therapy with axatilimab and ruxolitinib. This parameter change achieves cGVHD control while improving quality of life by avoiding the cumulative toxicities of long-term corticosteroid use.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful dependency on prolonged corticosteroids into a beneficial finite-duration combination therapy. By using axatilimab and ruxolitinib together, the therapy achieves comparable or superior cGVHD control with a more favorable safety profile that improves patient quality of life.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If conventional cGVHD treatments are used, then disease management is improved, but non-relapse mortality increases

Engineering Contradiction:

Improvedisease managementVSAvoidnon-relapse mortality

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic parameters by introducing a novel combination of axatilimab (CSF-1R antibody) and ruxolitinib (JAK inhibitor) that targets different pathways in cGVHD pathogenesis. This parameter change improves disease management effectiveness while reducing non-relapse mortality by avoiding the toxicities of conventional corticosteroid therapy.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite therapeutic strategy combining a monoclonal antibody and a small molecule JAK inhibitor that work through complementary mechanisms. This composite approach enhances disease management while reducing mortality risk by avoiding the harmful effects of conventional treatments.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy effectively targets and reduces cGVHD symptoms, offering an alternative to corticosteroids with reduced side effects and improved patient outcomes.

Implementation Method 1

The JAK inhibitor is a JAK1 inhibitor, a JAK2 inhibitor, or a JAK 1/2 inhibitor

Methodology Applied

Scientific EffectKinase inhibition:

Implementation Method 2

an antibody that binds to colony stimulating factor 1 receptor (CSF-1R)

Methodology Applied

Scientific EffectReceptor binding:

Data Source

PatentUS20250325664A1Combination therapy with an Anti-colony stimulating factor 1 receptor antibody and a JAK inhibitor

Publication Date: 2025.10.23 INCYTE CORP

AI summary

The present disclosure describes a combination of an anti-colony stimulating factor 1 receptor antibody and a JAK inhibitor for the treatment of chronic graft-versus-host disease.